February 29, 2008


Researchers are increasingly turning to new, innovative therapies, based on particles measuring less than 200 nanometers. At that scale, particles passively target weaker-walled cancer cells and help localize treatment, increasing its effectiveness while minimizing damage to healthy tissue. . . .

Developments in this field have accelerated since then, according to Piotr Grodzinski, Director of the NCI’s Alliance. “If you look at where we were five years ago, there was nothing mature enough that the FDA would even consider [it]. Today, there are 20 to 30 small companies in both diagnostics and therapeutics. A handful of those are in clinical trials, and we expect another three or four will file applications this year.”

Bring it on! (Via Nanodot).

Plus, at the Los Angeles Times, a nanotechnology debate. Some related thoughts of mine can be found here.